Evidence map›Paper›PMID 40341892›Full record

ArticleScientific reports2025

Risk profiling for cirrhosis and hepatocellular carcinoma in HFE hemochromatosis using mobilizable iron stores and alcohol consumption.

Natasha D P Mitchell, Timothy G St Pierre, Louise E Ramm, Grant A Ramm, John K Olynyk

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Natasha D P MitchellDepartment of Gastroenterology, Fiona Stanley Hospital, Murdoch, WA, Australia.
Timothy G St PierreSchool of Physics, Mathematics, and Computing, The University of Western Australia, Perth, WA, Australia.
Louise E RammHepatic Fibrosis Group, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Grant A Ramm *Hepatic Fibrosis Group, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
John K Olynyk *Department of Gastroenterology, Fiona Stanley Hospital, Murdoch, WA, Australia. John.olynyk@curtin.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HFE hemochromatosis (HH) may cause cirrhosis and hepatocellular carcinoma (HCC). Progression to these endpoints depends on the severity of iron overload and cofactors, such as alcohol. We evaluated alcohol and iron-related risk factors in relation to cirrhosis at diagnosis and future development of HCC in a retrospective analysis of 197 HH subjects. The proportion of subjects either with cirrhosis or who developed HCC during follow-up were 29/197 (14.7%) or 10/197 (5.1%), respectively. The median (IQR) follow-up time after diagnosis was 15.2 (4.6 to 22.1) years. The median mobilizable iron stores and daily alcohol consumption (IQR) were 6.0 (3.8-11.0) g and 20 (0-40) g, respectively. An optimal logistic regression model for the odds of cirrhosis was developed by adding candidate liver insult variables (mobilizable iron, alcohol consumption, and age as a surrogate for duration of exposure) in a forward stepwise strategy using area under the receiver operating characteristic curve (AUROC) analysis and the corrected Akaike information criterion. This model demonstrated an AUROC (95% CI) of 0.966 (0.935-0.996), with sensitivity 76 (58-88)% and specificity 97 (93-99) % for prediction of cirrhosis and had a negative predictive value of 99.4 (95% CI 96.7-99.97) % for development of HCC. Thus, future risk of HCC can be assessed from mobilizable iron stores and alcohol consumption of HH subjects.

Indexed as

Alcohol DrinkingCarcinoma, HepatocellularHemochromatosisHemochromatosis ProteinIronLiver CirrhosisLiver NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsROC CurveHemochromatosis ProteinHFE protein, humanIronHepatic iron concentration (HIC)Hepatic iron index (HII)Hepatocellular carcinoma (HCC)HFE hemochromatosis (HH)Mobilizable iron (MobFe)

Identifiers

PMID40341892
PMCPMC12062215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.